Lifecore Biomedical Inc Stock Price, News & Analysis

Lifecore Biomedical (NASDAQ: LFCR), a contract development and manufacturing organization (CDMO), has announced equity inducement grants for a newly hired employee. The compensation committee approved 15,000 restricted stock units (RSUs) and stock options for 30,000 shares on September 22, 2025.

The RSUs will fully vest after three years, while the stock options will vest one-third after the first year and 1/36th monthly thereafter. The stock options have a seven-year term and an exercise price at Fair Market Value. These grants were made under Lifecore's Equity Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Lifecore Biomedical (NASDAQ: LFCR), a contract development and manufacturing organization (CDMO), announced its participation in the 24th Annual Contract Pharma Contracting and Outsourcing Conference as a Gold Sponsor. The event will take place on September 18-19, 2025, in New Brunswick, NJ.

The company will showcase its injectables development and manufacturing expertise at Table 35, highlighting its 40+ year track record and state-of-the-art isolator-based filling capacity. This participation aligns with Lifecore's three-pronged growth strategy focused on expanding existing customer relationships, advancing late-stage development portfolio, and attracting new business.

Lifecore Biomedical (NASDAQ: LFCR), a contract development and manufacturing organization (CDMO), has announced its participation in three upcoming investor conferences in September 2025.

The company will participate in the Morgan Stanley Global Healthcare Conference (Sept 8-10) featuring a fireside chat, the Barrington Research Virtual Fall Investment Conference (Sept 16), and the Jefferies CDMO Summit (Sept 17). The Morgan Stanley fireside chat will be webcast live and available for replay on Lifecore's investor website.

Lifecore Biomedical (NASDAQ: LFCR) reported its Q4 and fiscal year 2025 results, achieving $128.9 million in FY2025 revenue, meeting guidance. The company signed nine new programs with new customers during FY2025, expanding beyond ophthalmic therapeutics. Q4 revenue was $36.4 million, down 4% year-over-year, with a net loss of $1.1 million.

Key developments include operational efficiency improvements, new leadership implementation, and plans to align fiscal year-end with the calendar year by December 31, 2025. The company maintains its commitment to achieving a 12%+ revenue CAGR and expanding adjusted EBITDA margins to over 25% in the mid-term. For the seven-month transition period through December 2025, Lifecore projects revenue of $74-76 million and adjusted EBITDA of $12-14 million.

Lifecore Biomedical (NASDAQ: LFCR), a contract development and manufacturing organization (CDMO), has scheduled its fourth quarter and fiscal year 2025 financial results announcement for August 7, 2025, after market close.

The company will host a webcast at 4:30 p.m. Eastern Time featuring senior management discussion of the results. The webcast will be accessible through Lifecore's investor relations website, with a replay available for 30 days following the live presentation.

Lifecore Biomedical (NASDAQ: LFCR), a contract development and manufacturing organization (CDMO), has announced equity inducement grants for three new employees. The compensation committee approved restricted stock unit (RSU) awards for 6,338 shares and stock options for 29,575 shares under the company's Equity Inducement Plan.

The RSUs will fully vest after three years, while the stock options will vest one-third after the first year and 1/36th monthly thereafter. The stock options have a seven-year term and an exercise price at Fair Market Value. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement for new employee recruitment.

Lifecore Biomedical (LFCR) has secured a significant 10-year commercial manufacturing and supply agreement with a key existing customer for a novel ophthalmic therapeutic. The agreement includes a multi-million-dollar statement of work for fill and finish CDMO services, including manufacturing Process Performance Qualification (PPQ) batches. This partnership represents a crucial milestone in Lifecore's growth strategy, particularly in advancing late-stage customer projects toward commercialization. CEO Paul Josephs emphasized the agreement's importance in generating substantial commercial manufacturing revenue from this established relationship while supporting the development of potentially impactful patient treatments.

Lifecore Biomedical (NASDAQ: LFCR) has received an accelerated payment of $10 million, representing the remaining balance from a previously announced $17 million equipment sale. The buyer opted to pay the full amount ahead of the original 18-month installment schedule, with $7 million already received in early 2025. The sale involved an excess high-speed, multi-purpose 10-head isolator filler sold to a non-competitive buyer. This development strengthens Lifecore's balance sheet and complements their recent installation of a high-speed 5-head filler, which supports up to $300 million in annual revenue generating capacity. The transaction aligns with the company's strategy of optimizing operations and aligning capital assets with operational needs.

Lifecore Biomedical (NASDAQ: LFCR) has appointed Mark DaFonseca as chief commercial officer. DaFonseca brings nearly 30 years of pharmaceutical industry experience, including over 15 years leading CDMO sales organizations. He most recently served as vice president of North American sales at CordenPharma. In his new role, DaFonseca will focus on elevating Lifecore's brand in the CDMO market by expanding the sales team, strengthening customer partnerships, and growing the business portfolio. As part of his appointment, Lifecore will grant DaFonseca 20,000 restricted stock units and options for 30,000 shares of common stock as inducement equity awards.